Biopharmaceutical company focused on developing novel therapies for patients with inflammatory and autoimmune diseases.
Acelyrin, Inc., a clinical-stage biopharmaceutical company, specializes in the identification, acquisition, and acceleration of transformative medicines aimed at addressing critical medical needs.
At the forefront of its pipeline is izokibep, the company's lead product candidate. Izokibep is a potent small protein therapeutic designed to inhibit IL-17A. Currently, it is undergoing Phase 3 clinical trials for the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis. Additionally, Phase 2 clinical trials are underway to explore its efficacy in treating Axial Spondyloarthritis.
Acelyrin is also advancing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody. This promising therapy is currently in Phase 1 clinical trials for the treatment of thyroid eye disease, addressing another critical area of unmet medical need.
Further expanding its innovative pipeline, the company is developing SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT. This candidate is in the preclinical stage, with potential applications envisioned for the treatment of chronic urticaria, underscoring Acelyrin's commitment to broad therapeutic solutions.
Founded in 2020 and headquartered in Agoura Hills, California, Acelyrin, Inc. continues to advance its mission of delivering novel treatments that can potentially transform patient outcomes across a spectrum of challenging medical conditions.